PMV Pharma Stock

pmvpharma.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $170.8MM

PMV is a biotechnology company dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

Register for Details

For more details on financing and valuation for PMV Pharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for PMV Pharma.

Register Today

Team

Management Team

David Mack Ph.D
Board Member, Co-Founder, Chief Executive Officer & President
Arnold Levine Ph.D
Board Member, Co-Founder & Member of Scientific Advisory Board
Thomas Shenk Ph.D
Co-Founder & Member of the Scientific Advisory Board
Binh Vu Ph.D
Vice President of Chemistry
Winston KUng
Chief Operating Officer & Chief Financial Officer
Thomas Davis Ph.D
Vice President of Biology

Board Members

Arnold Levine Ph.D
Peter Thompson MD
OrbiMed
Arnold Oronsky Ph.D
InterWest Partners
Steven Winick JD
Topspin Venture
David Mack Ph.D
Douglas Fisher MD
InterWest Healthcare Partners
Thilo Schroeder Ph.D
Nextech Invest

Other companies like PMV Pharma in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
PMV Pharma Appoints Salim Yazji, M.D. as Chief Medical Officer
/PRNewswire/ -- PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, today...
Updated on: Sep 23, 2023